Skip to main content

Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease

Journal of Neural Transmission volume 103, pages 433–446 (1996)Cite this article

Summary

High-performance liquid chromatography with electrochemical detection has been employed to analyze ultrafiltrates of cerebrospinal fluid of Parkinson's Disease (PD) patients and age-matched controls for the dopamine (DA) metabolites homovanillic acid (HVA) and 5-S-cysteinyldopamine (5-S-CyS-DA). The mean level of HVA in the CSF of PD patients, measured 5 days after withdrawal from L-DOPA therapy, was significantly lower than that measured in controls. By contrast, mean levels of 5-S-CyS-DA were not significantly different in the CSF of PD patients taking L-DOPA (PD-LT patients) the same patients 5 days after discontinuing this drug (PD-LW patients) or controls. However, the mean 5-S-CyS-DA/HVA concentration ratio was significantly (p < 0.05) higher in the CSF of PD-LW patients compared to controls. Although the PD patient population employed in this study had been diagnosed with the disease several years previously and had been treated with L-DOPA for prolonged periods of time the results of this study suggest that low CSF levels of HVA and a high 5-S-CyS-DA/HVA ratio together might represent useful markers for early diagnosis of PD. The high 5-S-CyS-DA/HVA ratio observed in the CSF of PD-LW patients also provides support for the hypothesis that the translocation of glutathione or L-cysteine into neuromelanin-pigmented dopaminergic cell bodies in the substantia nigra might represent an early event in the pathogenesis of PD.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Abbreviations

CSF :

cerebrospinal fluid

CySH :

L-cysteine

DA :

dopamine

DA-o-quinone :

dopamine-o-quinone

L-DOPA :

3,4-dihydroxyphenylalanine

DOPAC :

3,4-dihydroxyphenylacetic acid

EPI :

epinephrine

GSH :

glutathione

GSSG :

oxidized glutathione

5-HIAA :

5-hydroxyindole-3-acetic acid

HVA :

homovanillic acid

HO·:

hydroxyl radical

HPLC-EC :

high performance liquid chromatography with electrochemical detection

5-HT :

5-hydroxytryptamine (serotonin)

NE :

norepinephrine

PD :

Parkinson's disease

PD-LT :

Parkinson's disease patients taking L-DOPA therapy

PD-LW :

Parkinson's disease patients withdrawn from L-DOPA therapy for 5 days

5-S-CyS-DA :

5-S-cysteinyldopamine

5-S-Glu-DA :

5-S-glutathionyldopamine

SN :

substantia nigra

O 2·:

Superoxide radical anion

References

  • Adolfsson R, Gottfries CG, Roos BE, Winblad BJ (1979) Postmortem distribution of DA and homovanillic acid in human brain, variations related to age, and a review of the literature. J Neural Transm 45: 81–105

    Google Scholar 

  • Bernheimer H, Hornykiewicz O (1965) Herabgesetzte Konzentration der Homovanillinsäure im Gehirn von Parkinsonkranken Menschen als Ausdruck der Störung des zentralen Dopaminstoffwechsels. Klin Wochenschr 39: 1056–1059

    Google Scholar 

  • Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. J Neurol Sci 20: 415–455

    Google Scholar 

  • Calabrese V, Fariello RG (1988) Regional distribution of malonaldehyde in mouse brain. Biochem Pharmacol 37: 2287–2288

    Google Scholar 

  • Carlsson A, Fornstedt B (1991) Catechol metabolites in the cerebrospinal fluid as possible markers in the early diagnosis of Parkinson's disease. Neurology 41 [Suppl 2]: 50–52

    Google Scholar 

  • Carstam R, Brinck C, Hindemith-Augustsson A, Rorsman H, Rosengren E (1991) The neuromelanin of the human substantia nigra. Biochim Biophys Acta 1097: 152–160

    Google Scholar 

  • Cheng F-C, Juo J-S, Shih Y, Lai JS, Ni DR, Chia LG (1993a) Simultaneous measurement of serotonin, catecholamines and their metabolites in mouse brain homogenates by high-performance liquid chromatography with a microbore column and dual electrochemical detection. J Chromatogr 615: 225–236

    Google Scholar 

  • Cheng F-C, Tsai MH, Cheng WY, Kuo JS, Jen J-F, Liu TS (1993b) Rapid and improved simultaneous measurement of serotonin, catecholamines, and their metabolites in mouse brain homogenates by HPLC with a dual amperometric detector. J Biomed Lab Sci 5: 165–180

    Google Scholar 

  • Chia L-G, Cheng F-C, Kuo J-S (1993) Monoamines and their metabolites in plasma and lumbar cerebrospinal fluid of Chinese patients with Parkinson's disease. J Neurol Sci 116: 125–134

    Google Scholar 

  • Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Lees A, Jenner P, Marsden CD (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52: 381–389

    Google Scholar 

  • Fariello RG, Ghilardi O, Peschechera A, Ramucci MT, Angelucci T (1988) Regional distribution of ubiquinones and tocopherols in the mouse brain: lowest content of ubiquinols in the substantia nigra. Neuropharmacology 27: 1077–1080

    Google Scholar 

  • Fornstedt B, Rosengren E, Carlsson A (1986) Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, DOPA and DOPAC in the brains of eight mammalian species. Neuropharmacology 25: 451–454

    Google Scholar 

  • Fornstedt B, Carlsson A (1989) A marked rise in 5-S-cysteinyl-dopamine levels in guineapig striatum following reserpine treatment. J Neural Transm 76: 155–161

    Google Scholar 

  • Fornstedt B, Brun A, Rosengren E, Carlsson A (1989) The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra. J Neural Transm [P-D Sect] 1: 279–295

    Google Scholar 

  • Gibb WRG, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 51: 757

    Google Scholar 

  • Gonzalez-Quevedo Garcia JC, Fernandez R, Fernandez L (1993) Monoamine metabolites in normal human cerebrospinal fluid and in degenerative disease of the central nervous system. Bol Estud Med Biol 41: 13–19

    Google Scholar 

  • Graham DG (1978) Oxidation pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14: 633–643

    Google Scholar 

  • Graham DG, Tiffany SM, Bell WR, Gutnecht WF (1978) Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine and related compounds towards C1300 neuroblastoma cells in vitro. Mol Pharmacol 14: 644–653

    Google Scholar 

  • Halliwell B, Gutteridge MC (1984) Oxygen toxicity, oxygen radicals, transition metal ions and disease. Biochem J 219: 1–14

    Google Scholar 

  • Hartikainen P, Reinikanee KJ, Soininen H, Sirvio J, Soikkei R, Riekkinen PJ (1992) Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis and normal controls. J Neural Transm [P-D Sect] 4: 53–68

    Google Scholar 

  • Hornykiewicz O (1982) Imbalance of brain monoamines and clinical disorders. Prog Brain Res 55: 419–429

    Google Scholar 

  • Hornykiewicz O (1989) Aging and neurotoxins as causitive factors in idiopathic Parkinson's disease — a critical analysis of neurochemical evidence. Prog Neuropsychopharmacol Biol Psychiatry 13: 319–328

    Google Scholar 

  • Hornykiewicz O, Kish SJ (1986) Biochemical pathophysiology of Parkinson's disease. Adv Neurol 45: 19–34

    Google Scholar 

  • Jellinger K (1986) An overview of morphological changes in Parkinson's disease. Adv Neurol 45: 1–16

    Google Scholar 

  • Jenner P, Dexter DT, Sian J, Schapira AHV, Marsden DC (1992) Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. Ann Neurol [Suppl] 32: S82-S87

    Google Scholar 

  • Jenner P, Schapira AHV, Marsden CD (1992) New insights into the cause of Parkinson's disease. Neurology 42: 2241–2250

    Google Scholar 

  • Kish SJ, Morito C, Hornykiewicz O (1986) Glutathione peroxidase activity in Parkinson's disease brain. Neurosci Lett 58: 343–346

    Google Scholar 

  • Kish SJ, Shannak K, Hornykiewicz O (1988) Uneven patterns of DA loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 318: 876

    Google Scholar 

  • Mann DMA, Yates O (1983) Possible role of neuromelanin in the pathogenesis of Parkinson's disease. Mech Ageing Dev 21: 193–203

    Google Scholar 

  • Meister A (1974) Metabolism and function via the γ-glutamyl cycle. Life Sci 15: 177–190

    Google Scholar 

  • Perry TL, Yong VW (1986) Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in substantia nigra of patients. Neurosci Lett 67: 269–274

    Google Scholar 

  • Philbert MA, Beiswanger CM, Waters DK, Reuhl KR, Lowndes HE (1990) Cellular and regional distribution of reduced glutathione in the nervous system of the rat: histochemical localization by mercury orange and o-pathalaldehyde-induced histofluorescence. Toxicol Appl Pharmacol 107: 215–227

    Google Scholar 

  • Price KS, Parley IJ, Hornykiewicz O (1978) Neurochemistry of Parkinson's disease: relation between striatal and limbic dopamine. In: Roberts PJ, Woodruff GN, Iversen LL (eds) Dopamine: advances in biochemical psychopharmacology, vol 19. Raven Press, New York, pp 293–309

    Google Scholar 

  • Raps SR, Lai JCK, Hertz L, Cooper AJL (1989) Glutathione is present in high concentrations in cultured astrocytes but not in cultured neurons. Brain Res 493: 398–401

    Google Scholar 

  • Riederer P, Sofie E, Rausch E, Schmidt B, Reynolds G, Jellinger K, Youdim MBH (1989) Transition metals, ferritin, glutathione and ascorbic acid in Parkirisonian brain. J Neurochem 52: 515–520

    Google Scholar 

  • Rodgers AD, Curzon G (1975) Melanin formation by human brain in vitro. J Neurochem 24: 1123–1129

    Google Scholar 

  • Rosengren E, Linder-Eliasson E, Carlsson A (1985) Detection of 5-S-cysteinyldopamine in human brain. J Neural Transm 63: 247–253

    Google Scholar 

  • Roston DA, Kissinger PT (1982) Series dual-electrode detector for liquid chromatography/electrochemistry. Anal Chem 54: 429–436

    Google Scholar 

  • Sagara J-I, Miura K, Bannai S (1993) Maintenance of neuronal glutathione by glial cells. J Neurochem 61: 1672–1676

    Google Scholar 

  • Saggu H, Cooksey J, Dexter D, Wells FR, Lees AJ, Jenner P, Marsden CDA (1989) A selective increase in particulate Superoxide dismutase activity in Parkinsonian substantia nigra. J Neurochem 53: 692–697

    Google Scholar 

  • Scatton B, Rouquier L, Javoy-Agid F, Agid Y (1982) Dopamine deficiency in the cerebral cortex in Parkinson's disease. Neurology 32: 1039–1040

    Google Scholar 

  • Schapira AHV, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD (1990) Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54: 823–827

    Google Scholar 

  • Sian J, Dexter DT, Jenner P, Marsden DC (1992) Glutathione-related enzymes in brain in basal ganglia degenerative disorders. Br J Pharmacol 107 [Suppl]: 428P

  • Slivka A, Mytilineou C, Cohen G (1987) Histochemical evaluation of glutathione in brain. Brain Res 409: 275–284

    Google Scholar 

  • Sofic E, Riederer P, Heisen H, Bechmann H, Reynolds GP, Habenstreit G, Youdim MBH (1988) Increased iron (III) and total iron content in postmortem substantia nigra in Parkinsonian brains. J Neural Transm 74: 199–205

    Google Scholar 

  • Sofie E, Paulus W, Jellinger K, Riederer P, Youdim MBH (1991) Selective increase of iron in substantia nigra zona compacta of Parkinsonian brains. J Neurochem 56: 978–982

    Google Scholar 

  • Wick MM (1978) Dopamine: a novel antitumor agent active against B-16 melanoma in vivo. J Invest Dermatol 71: 163–164

    Google Scholar 

  • Wisser H, Ratge D (1989) Catecholamines in urine, blood and cerebrospinal fluid. In: Przuntek H, Riederer P (eds) Early diagnosis and preventive therapy in Parkinson's disease. Springer, Wien New York, pp 197–204

    Google Scholar 

  • Zhang F, Dryhurst G (1993) Oxidation chemistry of dopamine: possible insights into the age-dependent loss of dopaminergic nigrostriatal neurons. Bioorg Chem 21: 392–410

    Google Scholar 

  • Zhang F, Dryhurst G (1994) Effects of L-cysteine on the oxidation chemistry of dopamine: new reaction pathways of potential relevance to idiopathic Parkinson's disease. J Med Chem 37: 1084–1098

    Google Scholar 

  • Zhang F, Dryhurst G (1995) Influence of glutathione on the oxidation chemistry of the catecholaminergic neurotransmitter dopamine. J Electroanal Chem Interfac Electrochem 398: 117–128

    Google Scholar 

Download references

Author information

Author notes

  1. L. -G. Chia

    Present address: Section of Neurology, Taichung Veterans General Hospital, Taichung, Taiwan, Republic of China

Affiliations

  1. Department of Medical Research and Geriatrics Medical Center, Taichung Veterans General Hospital, Taichung, Taiwan, Republic of China

    F. -C. Cheng & J. -S. Kuo

  2. Department of Chemistry and Biochemistry, University of Oklahoma, Norman, OK, USA

    G. Dryhurst

Authors
  1. F. -C. Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. -S. Kuo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. -G. Chia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Dryhurst
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Cheng, F.C., Kuo, J.S., Chia, L.G. et al. Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease. J. Neural Transmission 103, 433–446 (1996). https://doi.org/10.1007/BF01276419

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01276419

Keywords

  • 5-S-cysteinyldopamine
  • homovanillic acid
  • cerebrospinal fluid
  • parkinson's disease